The motivation for the work stems from a persistent gap in regenerative biology. Chronic and acute pulmonary diseases, including chronic obstructive pulmonary disease, asthma, pneumonia and bronchiectasis, all involve damage to the bronchial epithelium, and impaired airway regeneration worsens disease progression. Scientists already knew that airway progenitors can mobilize to repair the alveoli, a one-way street of cross-compartmental help. In vitro studies had even suggested that human AT2 cells can become airway basal cells and bronchiolar secretory cells, and similar behavior had been observed in non-human primate injury models. But definitive in vivo evidence was missing, largely because the genetic tools available could not cleanly separate the cell populations involved.

The central technical obstacle was a marker problem. The standard lineage-tracing system for AT2 cells relies on the Sftpc-creER driver, which labels any cell expressing the Sftpc gene. Unfortunately, both genuine AT2 cells and bronchioalveolar stem cells (BASCs), a rare multipotent population sitting at the bronchioalveolar-duct junction that co-expresses Scgb1a1 and Sftpc, light up with this marker. Because BASCs are naphthalene-resistant and known to convert into club cells after injury, any experiment using Sftpc-creER alone could not tell whether newly formed airway cells came from AT2 cells or from BASCs. To break this ambiguity, the team built a series of five complementary dual-recombinase tracing systems that distinguish AT2 cells, BASCs and club cells from one another with unprecedented precision.

The first system, called AT2-tracer1, combined Sftpc-creER labelling with a newly generated Scgb1a1-DTR-GFP knock-in line. In triple transgenic mice, AT2 cells carried only the tdTomato reporter, while club cells and BASCs additionally carried GFP and a diphtheria toxin receptor. Administering diphtheria toxin selectively eliminated all Scgb1a1-expressing cells, wiping out the club cell lining of the bronchioles while leaving pure tdTomato-positive AT2 cells in the alveoli. Four weeks later, lineage tracing revealed that tdTomato-labelled AT2 cells had migrated into the bronchioles and generated tdTomato-positive, GFP-positive club cells. Quantification showed that 77.42 percent, give or take 4.71 percent, of the new club cells originated from AT2 cells, an astonishingly large contribution from a cell type previously thought to stay home.

The AT2-derived cells proved remarkably versatile. Within the bronchioles they differentiated into club cells, AT1 cells, ciliated cells and undifferentiated AT2 cells, all while remaining within the epithelial layer. Clonal analysis using a Confetti multicolor reporter confirmed that individually labelled AT2 cells possess multipotent transdifferentiation capacity at the single-cell level. The researchers also mapped two migratory routes: one through the bronchioalveolar-duct junction, which dominated, and a second through transient channels in the bronchiolar wall lined by AT2-derived AT1-like cells, which served as a supplementary pathway. To rule out artifacts of the toxin-ablation model, the team repeated the experiments with naphthalene injury using a nested dual-recombinase reporter system, AT2-tracer2, and again found that roughly 43 percent of regenerated club cells were of AT2 origin. A third system, AT2-tracer3, allowed simultaneous comparison of club cells, BASCs and AT2 cells in the same mouse, revealing that AT2 cells contributed the majority, about 52 percent, of regenerated club cells, outpacing both BASCs and resident club cells themselves.

Single-cell RNA sequencing then exposed the molecular choreography underlying the fate switch. Pseudotime analysis identified a transient intermediate state marked by expression of Cldn4, the gene encoding the tight-junction protein claudin-4. As AT2 cells progressed through this CLDN4-positive stage, the alveolar program was gradually silenced and the airway secretory program was switched on, with Sftpc expression falling and Scgb1a1 rising. The team built a dedicated genetic system to trace these transient cells directly and found that 62 percent of new club cells passed through the CLDN4-positive intermediate. Critically, deleting Cldn4 in AT2 cells slashed their contribution to club cells from about 66 percent to about 25 percent, demonstrating that this intermediate state is not merely a passive waypoint but a functional requirement for efficient transdifferentiation.

The next question was what instructs the migrating alveolar cells to adopt an airway identity. The answer, it turns out, is Notch signalling delivered by the cells that survive injury. Single-cell analysis showed that Notch pathway genes were upregulated in AT2-derived club cells, and ligand-receptor interaction mapping pointed to JAG1 and JAG2 on residual ciliated cells engaging NOTCH1 and NOTCH2 on the incoming alveolar cells. Functional tests were decisive: deleting the Notch signal transducer Rbpj in AT2 cells nearly abolished club cell conversion, dropping AT2-derived club output from about 38 percent to under 2 percent, while forcing Notch activation through NICD overexpression boosted conversion to about 45 percent. Ablating ciliated cells or deleting Jag1 specifically in ciliated cells, or deleting Notch2 in AT2-derived cells, each independently impaired the transition. Notch therefore acts as a bidirectional rheostat, and when it is disrupted, alveolar cells pile up in the bronchioles without differentiating, thickening airway walls and impairing ventilation.

Equally compelling is the mechanism that summons AT2 cells to the injury site in the first place. Spatial transcriptomics revealed that bronchiolar injury triggers a localized, roughly threefold increase in peribronchiolar immune infiltration, with neutrophils and monocytes secreting the chemotactic factor SPP1, also known as osteopontin. This secreted molecule forms a concentration gradient radiating outward from the damaged bronchioles, and AT2 cells sense it through the integrin subunit ITGB1 on their surface. The evidence chain is thorough: recombinant SPP1 accelerated wound closure and Transwell migration of AT2-like cells in vitro; an SPP1 inhibitor blocked the migratory effect of immune cells in co-culture; pharmacological SPP1 inhibition in living mice reduced bronchiolar coverage by AT2-derived cells; and genetic deletion of Itgb1 in AT2 cells significantly impaired their migration, thickened bronchiolar walls and worsened small-airway function. Matrix metalloproteinases such as MMP9 and MMP14, induced in immune and stromal cells, likely help clear a physical path through the extracellular matrix.

One of the most reassuring aspects of the study is what happens over the long term. At four weeks after injury, AT2-derived club cells still carried residual alveolar and PATS-like transcriptional signatures, raising the question of whether they were truly equivalent to native airway cells. By six months, however, single-cell multi-omics showed that these cells had converged with BASC-derived and club-cell-derived populations at both the transcriptomic and epigenetic levels. The AT2-specific chromatin accessibility signature declined rapidly and stayed low, while club-cell-specific secretory and immune gene programs rose progressively. AT2-derived club cells even retained progenitor capacity, proliferating and generating ciliated cells after a secondary naphthalene challenge. In other words, prolonged repair resolves lineage-specific differences through maturation to a common functional endpoint.

The implications reach well beyond basic biology. Current clinical strategies for airway repair focus on airway-resident stem cells such as basal and secretory cells, but this work suggests AT2 cells could serve as an alternative, and arguably more accessible, cellular reservoir for airway regeneration, particularly given their ability to mature fully into functional club cells. The identification of SPP1-ITGB1 signalling as the migration cue and Notch activation as the fate switch offers two concrete molecular targets for enhancing cross-compartmental repair. The authors are careful to note the caveats: mouse and human lungs differ structurally, and whether a conserved AT2-to-club program exists in humans remains unresolved, though in vitro evidence from human and primate systems is suggestive. Questions also remain about whether AT2 cells pass through a BASC-like state and whether other niche cells contribute. Still, the demonstration that the lung’s two great compartments are connected by a two-way regenerative dialogue rewrites a core assumption of pulmonary biology and opens a genuinely new chapter in the search for therapies that rebuild damaged airways.

Subject of Research: Cross-compartmental transdifferentiation of alveolar type 2 stem cells driving bronchiolar epithelial regeneration in the mouse lung

Article Title: Alveolar stem cells transdifferentiate to drive bronchiolar regeneration

Article References: Liu, K., Liu, Z., Meng, X., Tang, M., Di, F., Wang, Z., Li, C., Yang, S., Zhang, Y., Yang, X., Lv, Z., Li, X., Jin, H., Pu, W., Zhao, H., Li, F., Sui, P., & Zhou, B. (2026). Alveolar stem cells transdifferentiate to drive bronchiolar regeneration. Nature. https://doi.org/10.1038/s41586-026-11127-w

Image Credits: AI Generated

DOI: 10.1038/s41586-026-11127-w

Keywords: alveolar type 2 cells, bronchiolar regeneration, lineage tracing, Notch signalling, SPP1, ITGB1, club cells, CLDN4, lung stem cells, transdifferentiation, ciliated cells, lung injury repair

The research team, led by Kaoru Furihata of Kochi Medical School, Kochi University, together with colleagues at the Kanagawa Cancer Center, Tokyo Metropolitan Tama Medical Center, and Chikamori Hospital, enrolled patients with resectable pancreatic cancer who were scheduled for surgery, some after a course of neoadjuvant chemotherapy with gemcitabine and S-1, a regimen conditionally recommended in Japan for resectable disease. The critical technical innovation was the source of the tissue: rather than relying on specimens obtained during the operation itself, the investigators used samples collected by endoscopic ultrasound-guided fine-needle aspiration biopsy, or EUS-FNAB, a minimally invasive procedure that is already standard practice in the diagnostic workup of pancreatic masses. This means the prognostic information is available at the very beginning of the clinical pathway, when treatment decisions still lie ahead rather than behind.

Measuring protein expression in tiny biopsy cylinders is a genuine technical challenge. Needle aspirates contain limited cellular material, often admixed with blood, necrotic debris, and desmoplastic stroma, the dense scar-like tissue that characterizes pancreatic tumors. The team addressed this by developing novel monoclonal antibodies against PODXL and ITGB1 and pairing them with an automated detection system designed to quantify staining reproducibly across specimens. Automated image-based quantification reduces the subjectivity that has historically plagued immunohistochemistry, where pathologists grading staining intensity by eye can disagree. By standardizing both the antibody reagents and the scoring pipeline, the researchers aimed to produce a biomarker that could, in principle, be reproduced across institutions rather than confined to a single expert laboratory.

The biology underlying the marker choice is rooted in cancer metastasis. PODXL is a transmembrane sialomucin of the CD34 family, best known for maintaining the filtration slit diaphragm of kidney podocytes, but in cancer it has been implicated in cell adhesion changes, invasiveness, and epithelial-mesenchymal transition, the program by which epithelial tumor cells acquire motile, invasive properties. ITGB1, the beta-1 subunit of multiple integrin receptors, mediates attachment of cells to collagen, laminin, and fibronectin in the extracellular matrix, and is a well-established driver of tumor cell migration, survival signaling, and resistance to chemotherapy. The hypothesis was straightforward: tumors in which both molecules are abundant may be particularly adept at detaching, invading, and colonizing distant sites, and therefore carry an intrinsically worse prognosis that is detectable even in a preoperative sample.

The results are striking in their magnitude. Among the primary cohort of 55 patients with resectable pancreatic ductal adenocarcinoma, 24 patients, or 43.6 percent, showed high expression of both PODXL and ITGB1, a group the investigators designated Both-high. The remaining 31 patients formed the comparison group. Median overall survival in the Both-high group was 1.99 years, whereas median survival had not been reached in the Others group at the time of analysis, with follow-up extending beyond 3.7 years. The hazard ratio was 3.77, with a 95 percent confidence interval of 1.74 to 8.18 and a log-rank p value of 0.0003, meaning the Both-high group faced nearly four times the risk of death at any given time point.

The association held up under scrutiny. In the subgroup of 37 patients who received neoadjuvant chemotherapy with gemcitabine and S-1 before surgery, the Both-high group again fared far worse, with a median overall survival of 2.59 years versus a median not yet reached in the others, a hazard ratio of 5.56, a 95 percent confidence interval of 2.03 to 15.21, and a log-rank p value of 0.0002. In multivariate analysis adjusting for other clinical variables, Both-high status remained an independent prognostic factor, with a hazard ratio of 4.41, a 95 percent confidence interval of 1.91 to 10.17, and a p value of 0.0005. Classification and regression tree analysis, a statistical technique that recursively splits patients into risk groups, identified Both-high status as the primary explanatory factor for prognostic discrimination, suggesting the marker dominates over conventional clinical variables in separating good from poor outcomes.

The authors were careful to characterize the incremental value of adding ITGB1 to PODXL as modest, supported by exploratory analyses using decision curve analysis and time-dependent area under the curve metrics reported in the supplementary material. Decision curve analysis evaluates whether a model improves clinical decision-making across a range of risk thresholds, while time-dependent AUC measures discrimination as survival time accrues. This kind of methodological honesty matters, because biomarker studies in oncology have a long history of promising signals that dissolve under independent validation. By quantifying exactly how much the two-marker combination adds over PODXL alone, the study gives future investigators a realistic benchmark rather than an inflated claim.

Equally important are the study’s stated limitations, which the authors articulate with unusual clarity. Because the analysis included only patients who ultimately reached surgical resection, the biomarkers should be understood as prognostic stratifiers, not as definitive predictive markers of neoadjuvant treatment efficacy or of loss of surgical opportunity. In other words, the test identifies which resected patients will do worse, but it has not yet been shown to forecast which patients will progress during chemotherapy and forfeit surgery altogether, the very scenario that motivates much of the interest in preoperative risk stratification. A small exploratory cohort of seven patients with borderline resectable disease was analyzed separately and cannot support firm conclusions. The authors explicitly call for future prospective interventional trials that include non-resected patients to determine whether biomarker-guided modification of treatment actually improves outcomes, a step that separates marker discovery from marker-informed clinical practice.

The clinical logic of the finding is nonetheless compelling. Neoadjuvant chemotherapy with gemcitabine and S-1 is conditionally recommended for resectable pancreatic cancer in Japan, yet a subset of patients loses the opportunity for surgery as their tumors progress during preoperative treatment. If a biopsy-based test performed at diagnosis can flag the patients most likely to follow an aggressive course, oncologists could, in future trials, test whether those patients need intensified regimens, alternative drug combinations such as gemcitabine plus nab-paclitaxel, earlier escalation to other modalities, or closer surveillance. Conversely, patients in the favorable group might be spared unnecessary treatment intensification. The fact that the required tissue is already obtained through EUS-FNAB in nearly every diagnostic pathway for suspected pancreatic cancer means the barrier to implementation is analytical rather than procedural: the biopsy is taken anyway, and the question is only what additional information can be extracted from it.

The study, conducted under the Declaration of Helsinki with institutional review board approval at all participating centers and written informed consent from every patient, was supported by Grants-in-Aid for Scientific Research (KAKENHI) and published open access. For a disease in which the five-year survival rate has stubbornly remained in the single digits despite decades of effort, any tool that sharpens prognostic precision before treatment begins deserves attention. The road from a 55-patient cohort to routine clinical use is long, and independent validation in larger and more diverse populations will be essential. But the concept that a two-protein stain on a routine needle biopsy could sort pancreatic cancer patients into meaningfully different risk categories before therapy starts represents exactly the kind of practical, testable advance that the field has been waiting for, and it sets the stage for the interventional trials that will determine whether this biomarker can change not just what clinicians predict, but what patients experience.

Subject of Research: Preoperative prognostic stratification of resectable pancreatic cancer using PODXL and ITGB1 expression in EUS-FNAB biopsy specimens

Article Title: Preoperative prognostic stratification of high-risk resectable pancreatic cancer: combined Podxl/itgb1 expression in EUS-FNAB specimens as a prognostic biomarker

Article References: Furihata, K., Sakaguchi, M., Ueno, M., Kobayashi, S., Yokose, T., Nakazono, A., Inoue, D., Hayashi, T., Okawa, Y., Furihata, M., Kurabayashi, A., Uchida, K., & Taniuchi, K. (2026). Preoperative prognostic stratification of high-risk resectable pancreatic cancer: combined Podxl/itgb1 expression in EUS-FNAB specimens as a prognostic biomarker. BMC Cancer. https://doi.org/10.1186/s12885-026-17094-9

Image Credits: AI Generated

DOI: 10.1186/s12885-026-17094-9

Keywords: pancreatic cancer, PODXL, ITGB1, EUS-FNAB, prognostic biomarker, neoadjuvant chemotherapy, gemcitabine and S-1, risk stratification, immunohistochemistry, overall survival, pancreatic ductal adenocarcinoma, biomarker